What is CBDA and what does it do?

CBDA (cannabidiolic acid) is the acidic precursor to CBD found in raw cannabis plants. Unlike CBD, CBDA exists naturally in live cannabis and hemp plants, particularly in high concentrations in certain cultivars. When cannabis is dried, cured, or heated through decarboxylation, CBDA converts to CBD at temperatures around 220°F (104°C). CBDA interacts differently with the endocannabinoid system compared to CBD. While CBD primarily works through indirect pathways, CBDA shows selective inhibition of COX-2 enzymes, similar to non-steroidal anti-inflammatory drugs (NSAIDs). Research indicates CBDA has approximately 100 times greater affinity for 5-HT1A serotonin receptors than CBD, suggesting potential applications for nausea and anxiety. Preliminary studies suggest CBDA may offer several therapeutic properties. A 2013 study published in the British Journal of Pharmacology found CBDA effective in reducing nausea and vomiting in animal models. Research from 2020 indicated potential anti-seizure properties, with CBDA showing efficacy at lower doses than CBD in certain seizure models. CBDA concentrations vary significantly across cannabis strains. High-CBD cultivars like Charlotte's Web or ACDC can contain 15-20% CBDA by dry weight before decarboxylation. The compound is typically consumed through raw cannabis juicing, tinctures specifically formulated to preserve acidic cannabinoids, or minimally processed extracts stored under controlled conditions. The legal status of CBDA follows similar frameworks to CBD. Under the 2018 Farm Bill, hemp-derived CBDA containing less than 0.3% Delta-9 THC is federally legal in the United States, though state regulations vary. **Disclaimer: This information is for educational purposes only and should not be considered medical advice. Consult healthcare professionals before using cannabis products for therapeutic purposes. CBDA research remains preliminary, and more clinical studies are needed to establish definitive therapeutic applications.**